Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Dyne readies FDA push after DMD exon 51 med excels in trial
The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Eric Sagonowsky
Dec 8, 2025 10:50am
Capricor sets up 2nd DMD approval attempt with ph. 3 win
Dec 3, 2025 11:11am
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
Capricor responds to cell therapy snub, disputes FDA’s concerns
Sep 9, 2025 11:44am
Keros shakes up leadership structure to go all in on DMD drug
Aug 7, 2025 6:15am
